Logo image of GLTO

GALECTO INC (GLTO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GLTO - US36322Q2066 - Common Stock

23.74 USD
+1.92 (+8.8%)
Last: 1/13/2026, 2:59:34 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GLTO. GLTO was compared to 528 industry peers in the Biotechnology industry. The financial health of GLTO is average, but there are quite some concerns on its profitability. GLTO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GLTO has reported negative net income.
In the past year GLTO has reported a negative cash flow from operations.
In the past 5 years GLTO always reported negative net income.
GLTO had a negative operating cash flow in each of the past 5 years.
GLTO Yearly Net Income VS EBIT VS OCF VS FCFGLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -147.58%, GLTO is not doing good in the industry: 83.90% of the companies in the same industry are doing better.
GLTO's Return On Equity of -197.88% is on the low side compared to the rest of the industry. GLTO is outperformed by 67.80% of its industry peers.
Industry RankSector Rank
ROA -147.58%
ROE -197.88%
ROIC N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
GLTO Yearly ROA, ROE, ROICGLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

GLTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLTO Yearly Profit, Operating, Gross MarginsGLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLTO has more shares outstanding
Compared to 5 years ago, GLTO has less shares outstanding
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GLTO Yearly Shares OutstandingGLTO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GLTO Yearly Total Debt VS Total AssetsGLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -32.60, we must say that GLTO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GLTO (-32.60) is worse than 88.26% of its industry peers.
There is no outstanding debt for GLTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.6
ROIC/WACCN/A
WACCN/A
GLTO Yearly LT Debt VS Equity VS FCFGLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 3.73 indicates that GLTO has no problem at all paying its short term obligations.
GLTO's Current ratio of 3.73 is in line compared to the rest of the industry. GLTO outperforms 45.27% of its industry peers.
A Quick Ratio of 3.73 indicates that GLTO has no problem at all paying its short term obligations.
GLTO has a Quick ratio (3.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.73
Quick Ratio 3.73
GLTO Yearly Current Assets VS Current LiabilitesGLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

GLTO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.73%, which is quite impressive.
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.23% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.98%
EPS Next 2Y38.19%
EPS Next 3Y23.18%
EPS Next 5Y15.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLTO Yearly Revenue VS EstimatesGLTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 2033 200M 400M 600M
GLTO Yearly EPS VS EstimatesGLTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60 -80 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GLTO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLTO Price Earnings VS Forward Price EarningsGLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLTO Per share dataGLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

GLTO's earnings are expected to grow with 23.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.19%
EPS Next 3Y23.18%

More info and screens

0

5. Dividend

5.1 Amount

GLTO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GALECTO INC

NASDAQ:GLTO (1/13/2026, 2:59:34 PM)

23.74

+1.92 (+8.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06
Earnings (Next)03-17 2026-03-17/amc
Inst Owners49.37%
Inst Owner Change0%
Ins Owners3.57%
Ins Owner Change9.42%
Market Cap37.75M
Revenue(TTM)N/A
Net Income(TTM)-15.84M
Analysts85.71
Price Target36.72 (54.68%)
Short Float %11.76%
Short Ratio0.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)500%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)90.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.71
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-17.62
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-7.69
FCFYN/A
OCF(TTM)-7.69
OCFYN/A
SpS0
BVpS5.04
TBVpS5.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -147.58%
ROE -197.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.21%
ROA(5y)-74.46%
ROE(3y)-117.92%
ROE(5y)-83.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.73
Quick Ratio 3.73
Altman-Z -32.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.38%
EPS Next Y93.98%
EPS Next 2Y38.19%
EPS Next 3Y23.18%
EPS Next 5Y15.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.85%
OCF growth 3YN/A
OCF growth 5YN/A

GALECTO INC / GLTO FAQ

What is the fundamental rating for GLTO stock?

ChartMill assigns a fundamental rating of 2 / 10 to GLTO.


Can you provide the valuation status for GALECTO INC?

ChartMill assigns a valuation rating of 1 / 10 to GALECTO INC (GLTO). This can be considered as Overvalued.


What is the profitability of GLTO stock?

GALECTO INC (GLTO) has a profitability rating of 0 / 10.


How financially healthy is GALECTO INC?

The financial health rating of GALECTO INC (GLTO) is 6 / 10.


What is the expected EPS growth for GALECTO INC (GLTO) stock?

The Earnings per Share (EPS) of GALECTO INC (GLTO) is expected to grow by 93.98% in the next year.